A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL

This study is collecting real-world data on patients with a type of aggressive lymphoma called diffuse large B-cell lymphoma (DLBCL) who are receiving a treatment regimen that includes a drug called tucidinostat. Researchers specifically want to study patients with high-risk subtypes of this cancer to see how well this approach works in practice. **You may be eligible if...** - You are 18 years of age or older - You have been diagnosed with DLBCL and have not yet received any treatment for it - Your tumor has a high-risk feature such as double expression of MYC and BCL2 proteins, or specific genetic mutations (like TP53), or a MYC/BCL2 double hit - You are planned to receive or are currently receiving a treatment regimen that includes tucidinostat **You may NOT be eligible if...** - You have already received chemotherapy or other treatments for DLBCL - Your tumor does not have the high-risk features required by the study - You have serious organ function problems that would prevent safe treatment Talk to your doctor to see if this trial is right for you.